ACHM-025

ACHM-025 is a third-generation, AKR1C3-activated prodrug designed as a targeted therapy for aggressive T-cell acute lymphoblastic leukemia (T-ALL). It is selectively activated by the enzyme aldo-keto reductase family 1 member C3 (AKR1C3), which is highly expressed in T-ALL cells. Upon activation by AKR1C3 in the presence of NADPH, ACHM-025 releases a nitrogen mustard DNA alkylating agent that induces cytotoxicity specifically in cancer cells with high AKR1C3 expression. This selectivity aims to improve drug specificity and minimize off-target toxicity compared to traditional DNA alkylating agents like cyclophosphamide. Preclinical studies have demonstrated potent efficacy of ACHM-025 against T-ALL patient-derived xenografts, including chemoresistant models, and its activity correlates with AKR1C3 expression levels, suggesting potential for biomarker-driven patient selection[2][3][5][8][10].